The Tissue Core (CORE C) mandate is to provide a national resource that consists of a dataset of matched samples of frozen cells with corresponding pathological and clinical data. The Tissue Core is an integral and essential component of this proposal since it is the central repository for all samples. It maintains accurate records of the trafficking of all samples and facilitates the uniform sharing of information between all CRC projects. In addition, it facilitates and expedites the research of each CRC project and clinical trials by performing centralized standardized assays and distributing characterized samples to all members of this proposal. This Core ensures the long-term physical integrity of the biospecimen and maintains the privacy and confidentiality of the research participant.
The first aim of this Core is to serve as the central biorepository for all CLL samples diagnosed and collected from the participating clinical sites. This enables the uniform processing, storage, and distribution of all CLL samples used by the investigators of this proposal.
The second aim i s to perform a basic set of standardized assays on all viably stored CLL samples from each patient upon initial receipt, and as required by the clinical protocols.
The third aim i s to acquire serial samples during the disease progression of all CLL patients to enable longitudinal studies on the disease progression. CRC investigators can segregate cases that have indolent and non-progressive disease from those who have progressive disease or from those who have a change in the kinetics of disease progression.
The fourth aim, a multi-site service, is to organize and assure accurate scoring and high quality data entry associated with FISH for CLL among all CRC sites. This service provides reliable cytogenetic data for clinical trials and research correlations. The fifth aim is to characterize CLL samples based on their cellular kinetics. As an adjunct to these studies, the expressed immunoglobulin heavy chain genes (IGHV) about the leukemic clones can then be correlated to cellular kinetics to study the role for (auto) antigen drive in the clonal expansion. Lastly, the sixth aim is to manage the distribution and tracking of specific characterized samples as requested for hypothesis-driven studies of this proposal.

Public Health Relevance

This Core facilitates research designed to translate the findings of basic science into information useful in the clinical arena for CLL patients. It provides a national resource consisting of a dataset of matched samples with corresponding pathological and clinical data. This interactive information on each CLL sample allows for a better understanding of the biology of CLL and improved prognosis and clinical trials for this leukemia.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Diego
La Jolla
United States
Zip Code
Barr, Paul M; Robak, Tadeusz; Owen, Carolyn et al. (2018) Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica 103:1502-1510
Kondo, K; Shaim, H; Thompson, P A et al. (2018) Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway. Leukemia 32:960-970
Hasan, Md Kamrul; Yu, Jian; Widhopf 2nd, George F et al. (2018) Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood 132:170-178
Ten Hacken, Elisa; Valentin, Rebecca; Regis, Fara Faye D et al. (2018) Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight 3:
Gribben, John G (2018) How and when I do allogeneic transplant in CLL. Blood 132:31-39
Sivina, Mariela; Werner, Lillian; Rassenti, Laura et al. (2018) Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. Br J Haematol 180:597-600
Ott, Christopher J; Federation, Alexander J; Schwartz, Logan S et al. (2018) Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. Cancer Cell 34:982-995.e7
Balatti, Veronica; Tomasello, Luisa; Rassenti, Laura Z et al. (2018) miR-125a and miR-34a expression predicts Richter syndrome in chronic lymphocytic leukemia patients. Blood 132:2179-2182
Vangapandu, Hima V; Chen, Huiqin; Wierda, William G et al. (2018) Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma 59:1427-1438
Yu, Jian; Chen, Yun; Chen, Liguang et al. (2018) Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget 9:24731-24736

Showing the most recent 10 out of 562 publications